Cullinan Therapeutics

Cullinan Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing targeted therapies for autoimmune diseases and cancer. Its clinical-stage portfolio includes CLN-978, a wholly owned CD19xCD3 bispecific T cell engager being studied as an off-the-shelf subcutaneous therapy for rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease, and zipalertinib, a brain-penetrant EGFR exon 20 insertion inhibitor developed in partnership with Taiho Oncology for non-small cell lung cancer that reported positive Phase 3 REZILIENT3 results in September 2026. The company was founded in 2016, listed on Nasdaq in January 2021, and is led by President and Chief Executive Officer Nadim Ahmed.